644)			
	CERTIFICATE OF MAILING		
lence is being	deposited with the United States Postal Service as first	class mail in an envelope address	ed to
, Washington,	, D.C. 20231.		

1100

		ERTIFICATE OF MAILING					
	espondence is being deposited v Patents, Washington, D.C. 2023	with the United States Postal Service 1.	as first class n	nail in an envelope address	ed to:		
Typed or Printed Name	1 Name Wilhelm Palmen Jr.						
Signature	allen to line	n to low-		August 15, 2001	ECH CH		
010	MATION E STATEMENT	Attorney Docket	STAN190		T C		
INFUR		First Named Inventor	Zeng et al.		E N		
	§ 1.97(b)	Application Number	09/844,544				
		Confirmation Number	Unassigned		ER 160		
EMARKY		Filing Date	April 27, 2001		0/2900		
Address to: Assistant Commiss:	ioner for Patents	Group Art Unit	Unassigned				
Washington, D.C. 2		Examiner Name	Unassigned				
		Title: "Methods for Inhibition of Polyclonal β Cell Activation					

Sir:

4

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR § 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application; before the mailing date of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

Applicants feel that there are no fees required in association with the filing of this paper, however, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

> Respectfully submitted, **BOZICEVIC, FIELD & FRANCIS LLP**

and Immunoglobulin Class Switching to Pathogenic Autoantibodies by Blocking CD1-Mediated Interactions"

August 15, 2001

By: Pamela J. Sherwood, Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 327-3400

Facsimile: (650) 327-3231